Physician profile
Paul Ricca
NPI 1609937705
$1,834.01
in general payments reported to CMS, 2019-2025
16 companies · $92.43 in 2025
The $92.43 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $271 · 2021: $224 · 2022: $446 · 2023: $266 · 2024: $43.60 · 2025: $92.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $522.40 | 2019-2025 | |
| Amgen INC. | $336.63 | 2019-2022 | |
| Abbott Laboratories | $244.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $154.40 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $110.60 | 2022-2023 | Nucala |
| Novo Nordisk INC | $69.72 | 2020-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $68.12 | 2019-2022 | |
| Esperion Therapeutics, INC. | $57.66 | 2020-2022 | |
| Boston Scientific Corporation | $54.31 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $53.88 | 2022-2023 | Xarelto |
| Amarin Pharma, INC. | $41.69 | 2020-2021 | |
| Pfizer INC. | $26.74 | 2022 | |
| Lilly USA, LLC | $26.67 | 2023 | Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $24.81 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.68 | 2024 | Lifevest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $16.79 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ricca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.